It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
During labor, monocytes infiltrate massively the myometrium and differentiate into macrophages secreting high levels of reactive oxygen species and of pro-inflammatory cytokines (i.e. IL-1β), leading to myometrial contraction. Although IL-1β is clearly implicated in labor, its function and that of the inflammasome complex that cleaves the cytokine in its active form, has never been studied on steps preceding contraction. In this work, we used our model of lipopolysaccharide-induced preterm labor to highlight their role. We demonstrated that IL-1β was secreted by the human myometrium during labor or in presence of infection and was essential for myometrial efficient contractions as its blockage with an IL-1 receptor antagonist (Anakinra) or a neutralizing antibody completely inhibited the induced contractions. We evaluated the implication of the inflammasome on myometrial contractions and differentiation stages of labor onset. We showed that the effects of macrophage-released IL-1β in myometrial cell transactivation were blocked by inhibition of the inflammasome, suggesting that the inflammasome by producing IL-1β was essential in macrophage/myocyte crosstalk during labor. These findings provide novel innovative approaches in the management of preterm labor, specifically the use of an inflammasome inhibitor to block the precursor stages of labor before the acquisition of the contractile phenotype.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 INSERM U1231, Labex LIPSTIC and Label of Excellence from la Ligue Nationale Contre le Cancer, Dijon, France (GRID:grid.508062.9); University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313)
2 INSERM U1231, Labex LIPSTIC and Label of Excellence from la Ligue Nationale Contre le Cancer, Dijon, France (GRID:grid.508062.9); Hangzhou Normal University, School of Pharmacy, Hangzhou, China (GRID:grid.410595.c) (ISNI:0000 0001 2230 9154)
3 University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313)
4 Hangzhou Normal University, School of Pharmacy, Hangzhou, China (GRID:grid.410595.c) (ISNI:0000 0001 2230 9154)
5 INSERM U1231, Labex LIPSTIC and Label of Excellence from la Ligue Nationale Contre le Cancer, Dijon, France (GRID:grid.508062.9); University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); Cancer Center George-François Leclerc, Dijon, France (GRID:grid.5613.1)
6 INSERM U1231, Labex LIPSTIC and Label of Excellence from la Ligue Nationale Contre le Cancer, Dijon, France (GRID:grid.508062.9); University Hospital Besançon, Laboratory of Pharmacology-Toxicology, Platform PACE, Besançon, France (GRID:grid.411158.8) (ISNI:0000 0004 0638 9213); University of Franche-Comté, Faculty of Medicine and Pharmacy, Besançon, France (GRID:grid.7459.f) (ISNI:0000 0001 2188 3779)